Market cap
$327m
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
The Company’s activities will necessitate significant working capital through 2026 and beyond, and future cash requirements and the adequacy of its available funds will depend on many factors, primarily including the Company’s ability to generate revenue, the scope and costs of its commercial, manufacturing and process development activities, including the commercial launches of NEREUS TM and BYSANTI TM , a regulatory approval of Quimilza TM , the magnitude of its discovery, preclinical and clinical development programs and potential costs to acquire or license the rights to additional products. …Vanda Pharmaceuticals Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06